ARTICLE | Clinical News
Meloxicam: Phase III started
February 8, 2016 8:00 AM UTC
Recro began a double-blind, placebo-controlled Phase III trial to evaluate 30 mg IV meloxicam once daily for up to 3 doses in about 200 patients. Last April, Recro purchased meloxicam and its related ...